202 related articles for article (PubMed ID: 24726746)
1. Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric Plerixafor.
Li J; Oupický D
Biomaterials; 2014 Jul; 35(21):5572-9. PubMed ID: 24726746
[TBL] [Abstract][Full Text] [Related]
2. Polymeric Plerixafor: effect of PEGylation on CXCR4 antagonism, cancer cell invasion, and DNA transfection.
Wang Y; Li J; Oupický D
Pharm Res; 2014 Dec; 31(12):3538-48. PubMed ID: 24942536
[TBL] [Abstract][Full Text] [Related]
3. Balancing polymer hydrophobicity for ligand presentation and siRNA delivery in dual function CXCR4 inhibiting polyplexes.
Wang Y; Li J; Chen Y; Oupický D
Biomater Sci; 2015 Jul; 3(7):1114-23. PubMed ID: 26146552
[TBL] [Abstract][Full Text] [Related]
4. CXCR4-Targeted and Redox Responsive Dextrin Nanogel for Metastatic Breast Cancer Therapy.
Zhang F; Gong S; Wu J; Li H; Oupicky D; Sun M
Biomacromolecules; 2017 Jun; 18(6):1793-1802. PubMed ID: 28445650
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 pharmacogical inhibition reduces bone and soft tissue metastatic burden by affecting tumor growth and tumorigenic potential in prostate cancer preclinical models.
Gravina GL; Mancini A; Muzi P; Ventura L; Biordi L; Ricevuto E; Pompili S; Mattei C; Di Cesare E; Jannini EA; Festuccia C
Prostate; 2015 Sep; 75(12):1227-46. PubMed ID: 26073897
[TBL] [Abstract][Full Text] [Related]
6. IL-24 inhibits lung cancer cell migration and invasion by disrupting the SDF-1/CXCR4 signaling axis.
Panneerselvam J; Jin J; Shanker M; Lauderdale J; Bates J; Wang Q; Zhao YD; Archibald SJ; Hubin TJ; Ramesh R
PLoS One; 2015; 10(3):e0122439. PubMed ID: 25775124
[TBL] [Abstract][Full Text] [Related]
7. Chronic AMD3100 antagonism of SDF-1alpha-CXCR4 exacerbates cardiac dysfunction and remodeling after myocardial infarction.
Dai S; Yuan F; Mu J; Li C; Chen N; Guo S; Kingery J; Prabhu SD; Bolli R; Rokosh G
J Mol Cell Cardiol; 2010 Oct; 49(4):587-97. PubMed ID: 20655922
[TBL] [Abstract][Full Text] [Related]
8. Treatment of acute lung injury and early- and late-stage pulmonary fibrosis with combination emulsion siRNA polyplexes.
Wang Y; Ding L; Li Z; Chen G; Sun M; Oupicky D
J Control Release; 2019 Nov; 314():12-24. PubMed ID: 31644934
[TBL] [Abstract][Full Text] [Related]
9. Potential of CXCR4 antagonists for the treatment of metastatic lung cancer.
Burger JA; Stewart DJ; Wald O; Peled A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):621-30. PubMed ID: 21504328
[TBL] [Abstract][Full Text] [Related]
10. The CXCR4 antagonist plerixafor (AMD3100) promotes proliferation of Ewing sarcoma cell lines in vitro and activates receptor tyrosine kinase signaling.
Berning P; Schaefer C; Clemens D; Korsching E; Dirksen U; Potratz J
Cell Commun Signal; 2018 May; 16(1):21. PubMed ID: 29776413
[TBL] [Abstract][Full Text] [Related]
11. AMD3100 inhibits epithelial-mesenchymal transition, cell invasion, and metastasis in the liver and the lung through blocking the SDF-1α/CXCR4 signaling pathway in prostate cancer.
Zhu WB; Zhao ZF; Zhou X
J Cell Physiol; 2019 Jul; 234(7):11746-11759. PubMed ID: 30537000
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 antagonist delivery on decellularized skin scaffold facilitates impaired wound healing in diabetic mice by increasing expression of SDF-1 and enhancing migration of CXCR4-positive cells.
Liu H; Liu H; Deng X; Chen M; Han X; Yan W; Wang N
Wound Repair Regen; 2017 Aug; 25(4):652-664. PubMed ID: 28783870
[TBL] [Abstract][Full Text] [Related]
13. Chemokine (C-X-C motif) receptor 4 blockade by AMD3100 inhibits experimental abdominal aortic aneurysm expansion through anti-inflammatory effects.
Michineau S; Franck G; Wagner-Ballon O; Dai J; Allaire E; Gervais M
Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1747-55. PubMed ID: 24876351
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol Modification Enhances Antimetastatic Activity and siRNA Delivery Efficacy of Poly(ethylenimine)-Based CXCR4 Antagonists.
Wu P; Luo X; Wu H; Yu F; Wang K; Sun M; Oupicky D
Macromol Biosci; 2018 Nov; 18(11):e1800234. PubMed ID: 30259651
[TBL] [Abstract][Full Text] [Related]
15. Adenosine A2A receptor activation reduces brain metastasis via SDF-1/CXCR4 axis and protecting blood-brain barrier.
Chen L; Li L; Zhou C; Chen X; Cao Y
Mol Carcinog; 2020 Apr; 59(4):390-398. PubMed ID: 32037613
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologically antagonizing the CXCR4-CXCL12 chemokine pathway with AMD3100 inhibits sunlight-induced skin cancer.
Sarchio SNE; Scolyer RA; Beaugie C; McDonald D; Marsh-Wakefield F; Halliday GM; Byrne SN
J Invest Dermatol; 2014 Apr; 134(4):1091-1100. PubMed ID: 24226205
[TBL] [Abstract][Full Text] [Related]
17. Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion.
Li J; Zhu Y; Hazeldine ST; Li C; Oupický D
Angew Chem Int Ed Engl; 2012 Aug; 51(35):8740-3. PubMed ID: 22855422
[TBL] [Abstract][Full Text] [Related]
18. Pharmacology of AMD3465: a small molecule antagonist of the chemokine receptor CXCR4.
Bodart V; Anastassov V; Darkes MC; Idzan SR; Labrecque J; Lau G; Mosi RM; Neff KS; Nelson KL; Ruzek MC; Patel K; Santucci Z; Scarborough R; Wong RS; Bridger GJ; Macfarland RT; Fricker SP
Biochem Pharmacol; 2009 Oct; 78(8):993-1000. PubMed ID: 19540208
[TBL] [Abstract][Full Text] [Related]
19. Reversibly Stabilized Polycation Nanoparticles for Combination Treatment of Early- and Late-Stage Metastatic Breast Cancer.
Chen G; Wang Y; Wu P; Zhou Y; Yu F; Zhu C; Li Z; Hang Y; Wang K; Li J; Sun M; Oupicky D
ACS Nano; 2018 Jul; 12(7):6620-6636. PubMed ID: 29985577
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of SDF-1 receptors CXCR4 and CXCR7 attenuates acute pulmonary inflammation via the adenosine A
Konrad FM; Meichssner N; Bury A; Ngamsri KC; Reutershan J
Cell Death Dis; 2017 May; 8(5):e2832. PubMed ID: 28542132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
